Extrachromosomal DNA (ecDNA) amplification promotes high oncogene copy 24 number, intratumoral genetic heterogeneity, and accelerated tumor evolution 1-3 , 25 but its frequency and clinical impact are not well understood. Here we show, using 26 computational analysis of whole-genome sequencing data from 1,979 cancer 27 patients, that ecDNA amplification occurs in at least 26% of human cancers, of a 28 wide variety of histological types, but not in whole blood or normal tissue. We 29 demonstrate a highly significant enrichment for oncogenes on amplified ecDNA 30 and that the most common recurrent oncogene amplifications arise on ecDNA. 31
has recently emerged as a powerful mechanism for enabling tumors to concomitantly 48 reach high copy of growth promoting genes, while still maintaining intratumoral genetic 49 heterogeneity through its non-chromosomal mechanism of inheritance 1-3 . To date, 50 cytogenetic methods requiring live cells in metaphase have been used to infer 51 intranuclear localization of DNA amplifications and extrachromosomal status 10 . 52
Consequently, it has been challenging to accurately assess the frequency, distribution, 53 and clinical impact of ecDNA-based amplification. More recently computational analyses 54 of whole-genome sequencing data have suggested a relatively high frequency of ecDNA 55 in some cancer types 11, 12 . Here we set out to perform a global survey of the frequency of 56 ecDNA-based oncogene amplification, while investigating its contents and determining 57 its clinical context. 58
EcDNA are characterized by two distinguishing properties: 1. ecDNAs are highly and 59 focally amplified and 2. they are circular. These properties provide a basis for the 60 AmpliconArchitect tool, that enables detection and characterization of ecDNA from whole-61 genome sequencing data (Fig. 1A) 11 . We applied AmpliconArchitect 11 to whole-genome 62 sequencing data from The Cancer Genome Atlas (TCGA), to quantify and characterize 63 the architecture of amplified regions that are larger than 10kb and have more than 4 64 classified as 'Circular' (Extended Data Fig. 1A) representing amplicons residing 66 extrachromosomally or ecDNA structures that reintegrated into non-native chromosomal 67 locations as homogenously staining regions (HSRs), 'Amplified-noncircular' for linear 68 amplifications, or as 'heavily rearranged', for non-circular amplicons containing segments 69 from different chromosomes, or regions that were very far apart on chromosomes (>1Mb) 70 regions. Sample lacking amplifications were labeled 'no copy number amplification (CNA) 71 detected '. 72 To evaluate the accuracy of the computational predictions, we similarly analyzed whole 73 genome sequencing data from a panel of 34 cancer cell lines 1,2 , for which tumor cells in 74 metaphase could be examined. We used 15 unique fluorescence in-situ hybridization 75 (FISH) probes in combination with matched centromeric probes (60 distinct "cell-line, 76 probe" combinations) to determine the chromosomal or extrachromosomal location of a 77 set of amplicons. We observed that 100% of amplicons characterized as 'Circular' by 78 whole genome sequencing profile demonstrated extrachromosomal fluorescent signal 79 (Extended Data Fig. 1B) . Circular amplicons had a median count of 14.5 ecDNA per cell, 80 in contrast with the 'Amplified-noncircular' category, which had a median count of 0.0 81 ecDNA per cell. However, ecDNAs may be undercounted in amplicons with low copy 82 number. 'Heavily rearranged amplicons' showed at least one ecDNA per cell in two of five 83 cases, suggesting that this category consists of a mixture of chromosomal and 84 extrachromosomal amplifications. We excluded the more ambiguous category of 'heavily 85 rearranged' amplicons from futher comparisons, confining our analysis to 1,695 TCGA 86 samples. The analytic results of the 256 samples containing the more ambiguous 'heavily 87 rearranged amplicons' are presented in the supplement (Extended Data Fig. 2) . 88
We found that 436 (26%) of the 1,695 tumor samples carried one or more Circular 89 amplicons, suggesting that ecDNA-based amplification is a common event in human 90 cancer ( Fig. 1B) . In contrast, Circular amplifications were found in <0.5% of matched 91 whole blood or normal tissue samples, suggesting that extrachromosomal amplification 92 is a mechanism that is used primarily by cancer cells (Fig. 1B) . Of note, our analysis does 93 not reflect the presence of circulating cell free DNA in blood, or of small (<1 kb), circular, 94 acute myeloid leukemia and thryroid carcinoma, including at high frequency in many 97 cancers that are considered to be amongst the most aggressive histological types. The 98 distribution of Circular amplicon frequencies across the samples are consistent with 99 earlier results on cancer models, showing that ecDNA driven amplifications were a 100 defining feature of multiple cancer sub-types, but not normal cells 2 . 101
The chromosomal distribution of the 627 Circular amplicons was highly non-102 random (Fig. 1C) , more so when compared to the Amplified-noncircular regions 103 (Extended Data Fig. 3A ). We found that 41% of the 24 most recurrent amplified 104 oncogenes were most frequently present on Circular amplicons, with frequencies ranging 105 from 25% of samples for PAX8 to 91% for CDK4 (Fig. 1D) . The result carried over to a 106 larger list of 707 genes that were amplified in at least five samples, with 41% of those 107 oncogenes most frequently being amplified on circular structures (Extended Data Fig.  108 3B). We found that oncogenes amplified on circular amplicons achieved higher copy 109 numbers than the same oncogenes amplified on Amplified-noncircular structures 110 (Extended Data Fig. 3C ). We further observed that the association between ecDNA 111 structures and oncogene amplification did not extend to breakpoints. For 24 frequently 112 amplified oncogenes, the frequency of observing a specific number of breakpoints in a 113 unit interval decayed exponentially, consistent with random occurrence around the 114 oncogene ( Fig. 1E; Extended Data Fig. 3D, Extended Data Fig. 3E ). These results 115 suggest that ecDNA are formed through a random process, where selection for higher 116 copies of growth promoting driver oncogenes leads to rapid oncogene amplification 117 during cancer development and progression, in a way that also retains intratumoral 118 genetic heterogeneity, due to its mechanism of uneven inheritance 3, 16 . 119 Circular amplicons also differed from Amplified-noncircular amplifications in other 120 notable ways. Circular and Amplified-noncircular amplifications showed similar likelihood 121 of occurring in samples with chromosome-arm level aneuploidy (Extended Data Fig. 4A ) 122 and whole-genome duplication, which might arise as a result of chromosome 123 missegregation 17 or other mitotic errors 18 (Extended Data Fig. 4B ). Smaller and more 124 focal genomic gains and losses result from different mutagenic processes, associated 125 with genomic instability. We observed an increase in the number of DNA segments in 126 samples marked by Circular amplicons, compared to other categories ( Fig. 2A) . The 127 frequency of copy number losses was comparable between Circular and Amplified-128 noncircular amplicon samples (Extended Data Fig. 4C ), but genomic segment gains 129 were more frequently detected in samples with circular amplification ( Wilcoxon rank sum 130 test: p-val < 1e-14) (Extended Data Fig. 4D ). This observation coincided with a threefold 131 increase in gene fusion events inferred from matching RNAseq profiles ( Fig. 2B ; Binomial 132 test: p-value <1e-138) compared to Non-circular amplification. Clustered mutations, also 133 referered to as kataegis, were significantly more frequently detected in Circular amplicons 134 relative to Amplified-noncircular amplicons, suggesting increased incidence of kataegis 135 (Hypergeometric test: p-value≅ 0)(Extended Data Fig. 4E ). The majority of Circular 136 amplicon breakpoints showed no or minimal sequence homology (<5 bp), raising the 137 possibility that non-homologous end joining could be involved in ecDNA formation. In 138 contrast, Amplified-noncircular amplicon breakpoints showed significantly more micro-139 homologies than were seen on circular amplicons (Extended Data Fig. 4F , p-140 value<0.0005; two-sided Fisher's exact test). 141
We sought to examine the transcriptional consequences of circular ecDNA 142 amplification at the population level. We detected a highly significant correlation between 143 DNA copy number and gene expression level in all categories of DNA amplification, 144
Circular and Non-circular. However, at comparable DNA copy number, oncogenes on 145 Circular amplicons were significantly more highly expressed than those on Amplified-146 noncircular amplicons (p-value < 0.003; Wilcoxon rank sum test; amplifications and Amplified-noncircular regions, we analyzed the overlapping ATAC-seq 151 profiles available for 24 samples 19 . The results ( Fig. 3B) showed that chromatin of 152
Circular amplicons was significantly more accessible compared to Amplified-noncircular 153 categories (1.3 times higher ATAC-seq signal; Wilcoxon rank sum test; p-value < 0.003), 154
Having developed a way to stratify tumors based upon amplification architecture, 157
we examined the impact of ecDNA-based amplification on two hallmarks of cancer, 158 immune evasion and cell proliferation. We used previously developed gene expression 159 signatures 20 to evaluate the distribution of immune infiltrate and cell proliferation scores 160 by amplicon grouping. The cellular proliferation but not immune infiltration pathway 161 scores were significantly higher ( Fig. 4A , p-val < 1e-7; Wilcoxon Rank Sum Test; 162
Extended Data Fig. 6 ) in the Circular amplification category compared to the other two 163 groups. We did not observe difference in activity of the immune signature score 164 between groups (Fig. 4A , p-val < 0.03; Wilcoxon Rank Sum Test). The increased 165 activity of the cell proliferation gene signature suggested a higher rate of proliferation 166 and tumors that behave more aggressively. 167
To determine whether cancers that have ecDNA amplification were associated 168 with tumor progression, we examined the impact of circular amplification on lymph node 169 status at initial presentation, and overall survival. We found that the proportion of cases 170 in which the tumor had spread to a lymph node at the initial time of diagnosis was 171 significantly increased in tumor samples that had either circular or non-circular 172 amplification ( Fig. 4B ; p-value < 0.02 no-CNA vs Amplified-noncircular, p-value < 1.0e-173 05 Circular-amplicon vs Amplified-noncircular). Additionally, we found a significant 174 difference in overall survival of patients stratified by amplification category. Patients 175 whose tumors contained circular amplification associated with significantly worse overall 176 outcomes compared to patients whose tumors harbored either non-circular amplifications 177 or no amplifications ( Fig. 4C ; p-val < 1e-15 versus no-CNA detected; p-val < 0.07 against 178
Amplified-noncircular; Log-rank test). To account for the possibility that differences in 179 survival rate are being influenced by the disease subtype, as circular amplicons are much 180 more prevalent in aggressive cancers such as glioblastoma, we fit the data to a Cox 181
Hazard model that tested survival after controlling for disease subtype. The model 182 showed that patients with circular amplicons had significantly higher hazard rates (Fig. 183 4D; 28% increase in hazard rate relative to no-CNA, p-val < 0.03). 184
The 3D organization of the genome plays a critical role in determining how that genome 186 functions, or malfunctions, as occurs in cancer. The data presented here demonstrate 187 that ecDNA play a critical role in cancer, providing a mechanism for achieving and 188 maintaining high copy oncogene amplification and diversity. This mechanism of 189 amplification is operant in a large fraction of human cancers, and contributes to the poor 190 outcomes for patients. The potential to leverage the presence of ecDNAs in a quarter of 191 human cancers for diagnostics or therapeutics provides a link between cancer genomics 192 and broad utility for patient populations. 193 194 METHODS 195 AmpliconArchitect 196 We used AmpliconArchitect 11 infer the architecture of the `amplicons' ---large (>10kb) 197 rearrangements with high copy numbers (CN>4) that are inferred to have co-amplified 198 as a structure. AmpliconArchitect takes as an input aligned WGS sequences and seed 199 intervals of the amplicon. AmpliconArchitect then searches for other regions that belong 200 to the amplicon by exploring the seed intervals, and extends beyond the intervals if it 201 encounters copy number changes or discordant edges that support a breakpoint. The 202 collection of intervals and breakpoints are combined to form a fine network with nodes 203 representing segments and edges representing rearrangements, which we call the 204 breakpoint graph. This breakpoint graph is can be further decomposed into simple 205 cycles to identify any circular paths within the amplicon structure, which is indicative of 206 ecDNA presence. The detected amplicons were annoted with the Ensembl Release 75 207 gene database (GRCh37). 208 209
Amplicon and sample classification 210
As a perquisite, amplicons must contain ≥ 10kb of genomic segments amplified to at 211 least four copies above median ploidy in order to be considered a valid amplicon. We 212 then use the AmpliconArchitect derived breakpoint graph to classify amplicons into 213 three categories: 1. Circular amplification; 2. Heavily rearranged amplification; and, 3. 214 at least a copy count of four. Non-circular amplicons were denoted as heavily 217 rearranged if the breakpoints connect segments from different chromosomes, or distal 218 (>1Mb) regions (Extended Data Fig. 1A) . Non-circular, non-distal amplicons were 219 denoted as locally rearranged. All other regions that were not part of any amplicon 220 structure were classified as not-amplified. While an amplicon may fit the requirements 221 for several categories (i.e., a circular amplicon may also comprise heavily rearranged 222 amplifications), priority was given to the circular amplification category, followed by average number FISH probes that co-localized on ecDNA across all the images for that 237 particular cell line+FISH probe combination (Extended Data Fig. 1B) .
Wilcoxon Rank 238
Sum test was used to detect significant differences in average ecDNA counts per cell 239 across the amplicon classes. 240
TCGA processing 241
We processed TCGA whole genome sequencing BAMs through the Institute for 242
Systems Biology Cancer Genomics Cloud (https://isb-cgc.appspot.com/) that provides a 243 cloud-based platform for TCGA data analysis. We used genome-wide snp6 copy 244 number segments with copy number log ratio equal to 1 as seed interval(s) of interest 245 that are required for the input to AmpliconArchitect 11 . Default parameters and reference 246 files were used for all other settings. Details on how to run AmpliconArchitect have been 247 described in the corresponding manuscript 11 and its source code depository. 248
We ran AmpliconArchitect on tumor and normal WGS samples from 1979 patients. 
Oncogene analysis 260
We examined the enrichment of the 24 recurrent oncogenes known to be activated by 261 amplification by counting the total number of base pairs from the amplicon classes from 262 all the tumor samples that overlap these oncogenes. We then simulated 10,000 263 replicates by sampling random regions of the same size of the amplicons and computed 264 an empirical expected distribution of base pairs covering the oncogenes if the amplicons 265 were randomly sampled across the genome. We report the z-score between the 266 empirical distribution and observed value for the amplicon classes. We also report the 267 average copy count, estimated from AmpliconArchitect. For each of these oncogenes 268 on an amplicon structure, we reported the position of breakpoint detected within a 1 MB 269 region flanking the oncogene using the breakpoint graph to infer breakpoints. We 270 partitioned the region into 1000 bp windows and counted the total number of 271 breakpoints that landed in each window, and display a histogram of these counts. We 272 modeled the histograms using an exponential distribution and show that under the 273 assumption that the breakpoints are distributed randomly, the histograms closely follow 274 the exponential distribution. 275
We used allOnco (http://www.bushmanlab.org/links/genelists), a set of 2,579 cancer 276 genes generated from curated collections cancer genes from many different 277 publications. We identified all amplicons that overlapped with the oncogenes and report 278 the proportion amplified oncogenes that are circular. 279
Genomic instability analyses 280
We computed total copy number gains/losses as the number of snp6 copy number 281 segments with copy number >=4 or <= 1. Wilcoxon Rank Sum test was used to test for 282 a significant difference between the two distributions. We used the data from a previous 283 study 22 to estimate the genome doubling status and chromosomal arm duplication and 284 loss for each sample. Wilcoxon Rank Sum test was used to test significance between 285 the distribution of gains and losses and Chi-squared test was used to test significance 286 between the distribution of whole genome doublings. 287
We used the data from the TCGA fusion database (https://tumorfusions.org/) 23 to 288 identify fusions events that occur on an amplicon. For each fusion in the database, we 289 consider it valid if both ends of the fusion breakpoint junction occur on the same 290 amplicon. In total, 710 amplified fusions were detected. We computed the average 291 fusion events per 10 Mb as the total number of fusions that landed within an amplicon 292 class divided by the sum of all the base pairs of the amplicon class multiplied by 10e7. 293
To test whether circular amplicons were enriched fusion events, we computed the p-294 value of observing at least the number of fusion events on circular amplicon under a 295 binomial distribution where the probability p was estimated using the total number of 296 fusion events on the amplified-noncircular divided by the total base pairs of the 297 amplified non-circular event and the number of trials n as the total base pairs of the 298 circular amplicons. 299
RNAseq and ATACseq analyses 300
Of the 1,695 tumor samples, 1,608 had RNA-seq data in the format of FPKM-UQ 301 expression data. For each gene within each disease cohort, we computed a baseline 302 FPKM-UQ as the average FPKM-UQ of all samples for which the gene was not found 303 on an amplicon (i.e., average expression of the unamplified gene). We then computed 304 the fold-change in expression of each gene on each amplicon as the FPKM-UQ of the 305 amplified gene divided by the average FPKM-UQ of the unamplified samples, and 306 report the distribution of fold-changes versus the copy number. Tukey's range test was 307 used to test significance between slope of the FPKMs for circular and amplified-308 noncircular. 309 ATAC-seq profiles were available for 24 samples. For each amplicon in each sample, 310 fold-change in ATAC-seq signal was computed as the average ATAC-seq signal across 311 the amplicon region divided by the average ATAC-seq signal for the same region in the 312 unamplified samples of the same cancer type. Wilcoxon Rank Sum test was used to 313 test significance between the two distributions. 314
Kataegis 315
Localized mutation clusters (kataegis loci) were defined as having 6 or more 316 consecutive mutations with an inter-mutation distance of < 1kb in a similar way to a 317 previously used approach 24 . 318
Inferring breakpoint homologies 319
For each breakpoint, sequencing reads around +/-1000 bps of the breakpoint were 320 locally reassembled with SvABA 25 to produce a contiguous consensus sequence of 321 each breakpoint, precise breakpoint positions, and the level of homology at breakpoints. 322
Statistical analysis 323
Survival curves were estimated with the Kaplan-Meier method, and comparison of 324 survival curves between groups was performed with the log-rank test in R survival d. Fig. 1 | Frequency of circular amplification across tumor and non-tumor tissues. B . Distribution of circular, non-circular, and no copy number alteration (no CNA) detected categories by tumor and normal tissue. C. Genome-wide distribution of circular (red) and non-circular (blue) amplification peaks. D. Classification of circular vs non-circular amplification status by gene. Shown are 24 most frequently amplified oncogenes. TCGA copy number array data was used to count the total number of DNA segments within a sample. Circular samples contained statistically significantly more DNA segments than non-circular and no CNA detected (p-val < 1e-5 and 1e-128, respectively; Wilcox Rank Sum Test). B. Circular structures expressed significantly more gene fusions compared to non-circular amplicons, after size normalization. a.
Fig. 3 | Gene expression and chromatin accessibility of amplicon classes. A.
Copy number of the gene versus its fold-change in FPKM for all genes with a copy count greater than 4 and less than 100, for each gene on each amplicon. The fold-change in FPKM is computed as the gene's (FPKM-UQ+1) divided by the average of (FPKM-UQ+1) for the same gene in all other tumor samples from the same cohort for which the gene is not on any amplicon (i.e., not amplified). Linear regression lines are shown for each classification class. Tukey's range test shows genes on circular structures are significantly different to genes on non-circular structures (p-value < 1e-15). B. For each amplicon in the 24 TCGA samples with ATAC-seq and AmpliconArchitect results, the log2 fold-change in ATAC-seq signal across the amplicon relative to tissue types without amplification within the same region is shown. Each point represents a separate amplicon. The distribution of foldchange for circular amplicons is statistically significantly higher than non-circular (Wilcoxon rank sum test; p-value < 0.003). 
a.
Extended Data Fig. 1 | Amplicon classification. A. Schematic representation of the three classification categories. Amplicons are classified using a hierarchical scheme based upon the genomic reconstruction of the amplified regions (i.e., any region with a copy count of 4 or greater) and the presence or absence of discordant edges between these regions. Amplicons must have a minimum 10kb of amplified regions in order to be considered a valid amplicon. The first category is circular amplicon, which is an amplicon that contains one or more amplified segments forming a cyclic path of at least 10kb bps in length and has an average amplification of four copies. The second category is heavily-rearranged amplicon, which is an amplicon that contains amplified segments that are connected by discordant read pairs, and at least one breakpoint junctions is inter-chromosomal or greater than 1Mb is size. The third category is non-circular amplicon, which is any amplicon that contains amplified segments with no discordant edges or with discordant edges, but all breakpoint junctions are less than 1 Mb in size. All other regions are considered not amplified. As the classification scheme is hierarchical, each amplicon can only have one class, and the highest rank class has precedent (i.e., an amplicon that is both circular and heavily-rearranged will be classified only as circular). As samples can have multiple amplicons, the sample is classified as the amplicon with highest precedent (i.e., a sample with 1 circular amplicon and 3 heavily-rearranged amplicons would be classified as circular).
b.
Extended Data Fig. 1 | Amplicon classification c. Fig. 3 . Circular vs amplified non-circular amplification comparisons. A. 24 recurrently amplified oncogenes significantly overlap circular regions (z-score 10.9), especially compared to amplified non-circular (z-score 4.0). B. For all oncogenes with copy number >= 4 (defined from the DNA copy number array data) and present in at least 5 samples, we show the class distribution of that oncogene. The oncogenes are ordered by proportion on circular amplification. C. For the 24 recurrent oncogenes known to be activated via amplification (Zack et al. Nat Gen. 2013), we report the average copy number for the oncogenes for circular amplification versus amplified-noncircular amplification. Fig. 3 . Circular vs amplified non-circular amplification comparisons. D. Breakpoint locations across the 24 recurrent oncogenes activated by amplification. Outliers in CCND1 and MDM2 were results of mapping bias due to short ALU repeats near the oncogene region. a. b.
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Extended Data Fig. 4 | Aneuploidy and genomic instability events by amplification class. A. Chromosome arm aneuploidy scores showing no difference in chromosomal arm level events between amplified-noncircular and circular amplification. B. Genome doublings distribution across classes showing no difference in distribution between amplified-noncircular and circular amplification. Circular amplification and non-amplified are different (Chi-square test; p-val < 1e-12). Circular amplification and amplified-noncircular are not different (Chi-square test; pval < 0.10). C. Distribution for total DNA loss segments by amplification class. TCGA CNV array data was used to count the total number of DNA losses within a sample. A DNA loss was defined as a segment with CN <= 1. D. Same as C, but for gain segments (CN >=4). Circular samples contain statistically significantly more DNA gains than non-circular and no-CNA detected (p-val < 1e-14 and 1e-127, respectively; Wilcox Rank Sum Test). Non-circular contain statistically significantly more DNA gains than no-CNA detected (p-val < 1e-35). Fig. 4 | Aneuploidy and genomic instability events by amplification class. E. Kataegis frequency differences between amplification categories. Amplicons were grouped into Amplicon-size bins, and # kataegis frequency was normalized for the number of DNA breakpoints, demonstrating a higher occurrence of kataegis in Circular compared to Non-circular amplifications. The number of amplicons used is shown in parentheses. F. Breakpoint homology by amplification class. Note that inserted sequences were excluded.
Extended Data
Extended Data Fig. 5 | FPKM fold-change versus copy number.
For each gene on each amplicon, we report the copy number of the gene versus its fold-change in FPKM for all genes with a copy count greater than 4 and less than 100. The foldchange in FPKM is computed as the gene's (FPKM-UQ+1) divided by the average of (FPKM-UQ+1) for the same gene in all other tumor samples from the same cohort for which the gene is not on any amplicon (i.e., is not amplified). Linear regression lines are shown for each classification class. Tukey's range test shows genes on circular structures are significantly different to genes on non-circular structures (p-value < 1e-15).
Extended Data Fig. 6 | Circular amplification associates with worse outcomes.
Immune gene expression signature single sample GSEA (ssGSEA) scores by amplification category. Shown are means and 95% confidence intervals of the ssGSEA scores. No significant difference was observed between classes.
